• 1
    Morton DL. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma. Paper presented at: 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla.
  • 2
    Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007; 109: 100-108.
  • 3
    Sondak VK, Taylor JMG, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004; 11: 247-258.
  • 4
    Kesmodel SB, Karakousis CP, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005; 12: 449-458.
  • 5
    Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control. 2005; 12: 230-235.
  • 6
    Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003; 21: 1326-1331.
  • 7
    Agnese DM, Abdessalam SF, Burak WE, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003; 134: 542-547.
  • 8
    Schwartz JL, Wang TS, Hamilton TA, et al. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer. 2002; 95: 1562-1568.
  • 9
    Perrott RE, Glass LF, Reintgen DS, Fenske NA. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol. 2003; 49: 567-588.
  • 10
    Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 7-17.
  • 11
    Arora A, Lowe L, Su LD, et al. Wide excision without radiation for desmoplastic melanoma. Cancer. 2005; 104: 1462-1467.
  • 12
    Su LD, Fullen DR, Lowe L, et al. Desmoplastic and neurotropic melanoma. Analysis of 33 patients with lymphatic mapping and sentinel node biopsy. Cancer. 2004; 100: 598-604.
  • 13
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992; 127: 392-399.
  • 14
    Jacobs IA, Chang CK, Salti G. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Am Surg. 2004; 70: 59-62.
  • 15
    Cherpelis BS, Haddad F, Messina J, et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol. 2001; 44: 762-766.
  • 16
    Essner R, Chung MH, Bleicher R, et al. Prognostic implications of thick melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol. 2002; 9: 754-761.
  • 17
    Ferrone CR, Panageas KS, Busam KJ, et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002; 9: 637-645.
  • 18
    Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick primary melanoma. Ann Surg Oncol. 2000; 7: 160-165.
  • 19
    Carlson GW, Murray DR, Hestley A, et al. Sentinel lymph node mapping for thick melanoma: should we be doing it? Ann Surg Oncol. 2003; 10: 408-415.
  • 20
    Thompson JF, Shaw HM. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant and does removing positive regional nodes influence outcome? Ann Surg Oncol. 2002; 9: 719-722.
  • 21
    Gutzmer R, Satzger I, Thoms K-M, et al. Sentinel lymph node status is the most important prognostic factor for thick melanomas. J Dtsch Dermatol Ges. 2007; 6: 198-203.